WO2001085100A2 - Proteines de fusion et conjugues contenant un vasodilatateur et un agent thrombolytique - Google Patents

Proteines de fusion et conjugues contenant un vasodilatateur et un agent thrombolytique Download PDF

Info

Publication number
WO2001085100A2
WO2001085100A2 PCT/US2001/015209 US0115209W WO0185100A2 WO 2001085100 A2 WO2001085100 A2 WO 2001085100A2 US 0115209 W US0115209 W US 0115209W WO 0185100 A2 WO0185100 A2 WO 0185100A2
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
thrombolytic
vasodilator
fusion protein
conjugate
Prior art date
Application number
PCT/US2001/015209
Other languages
English (en)
Other versions
WO2001085100A3 (fr
Inventor
Vemuri B. Reddy
Ethan Lerner
Original Assignee
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation filed Critical The General Hospital Corporation
Priority to AU2001261423A priority Critical patent/AU2001261423A1/en
Publication of WO2001085100A2 publication Critical patent/WO2001085100A2/fr
Publication of WO2001085100A3 publication Critical patent/WO2001085100A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Insects & Arthropods (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une protéine de fusion ou un conjugué qui contient un vasodilatateur et un agent thrombolytique, ainsi que son utilisation.
PCT/US2001/015209 2000-05-11 2001-05-10 Proteines de fusion et conjugues contenant un vasodilatateur et un agent thrombolytique WO2001085100A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001261423A AU2001261423A1 (en) 2000-05-11 2001-05-10 Vasodilator-thrombolytic fusion proteins and conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56992000A 2000-05-11 2000-05-11
US09/569,920 2000-05-11

Publications (2)

Publication Number Publication Date
WO2001085100A2 true WO2001085100A2 (fr) 2001-11-15
WO2001085100A3 WO2001085100A3 (fr) 2002-04-04

Family

ID=24277454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015209 WO2001085100A2 (fr) 2000-05-11 2001-05-10 Proteines de fusion et conjugues contenant un vasodilatateur et un agent thrombolytique

Country Status (2)

Country Link
AU (1) AU2001261423A1 (fr)
WO (1) WO2001085100A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167104A1 (fr) * 2007-06-18 2010-03-31 BioChemics, Inc. Molécules synthétiques bifonctionnelles
WO2018129200A2 (fr) 2017-01-05 2018-07-12 The Regents Of The University Of California Agonistes du récepteur pac1 (maxcaps) et leurs utilisations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EGGENBERGER ET AL.: 'Maxadilan interacts with receptors for pituitary adenylyl cyclase activating peptide in human SH-SY5Y and SK-N-MC neuroblastoma cells' NEUROPEPTIDES vol. 33, no. 2, 1999, pages 107 - 114 *
HINCHEY ET AL.: 'Thrombolytic therapy in patients with acute ischemic stroke' ARCH. NEUROL. vol. 57, no. 10, October 2000, pages 1430 - 1436, XP002948630 *
OSAMU MORO ET AL.: 'Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type I receptor-specific antagonist' J. BIOL. CHEM. vol. 274, no. 33, 13 August 1999, pages 23103 - 23110 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2167104A1 (fr) * 2007-06-18 2010-03-31 BioChemics, Inc. Molécules synthétiques bifonctionnelles
EP2167104A4 (fr) * 2007-06-18 2014-08-06 Biochemics Inc Molécules synthétiques bifonctionnelles
WO2018129200A2 (fr) 2017-01-05 2018-07-12 The Regents Of The University Of California Agonistes du récepteur pac1 (maxcaps) et leurs utilisations
WO2018129200A3 (fr) * 2017-01-05 2018-08-09 The Regents Of The University Of California Agonistes du récepteur pac1 (maxcaps) et leurs utilisations
EP3565573A4 (fr) * 2017-01-05 2020-08-12 The Regents of The University of California Agonistes du récepteur pac1 (maxcaps) et leurs utilisations
US11186622B2 (en) 2017-01-05 2021-11-30 The Regents Of The University Of California PAC1 receptor agonists (MAXCAPS) and uses thereof

Also Published As

Publication number Publication date
AU2001261423A1 (en) 2001-11-20
WO2001085100A3 (fr) 2002-04-04

Similar Documents

Publication Publication Date Title
Beltzer et al. In vitro binding of the asialoglycoprotein receptor to the beta adaptin of plasma membrane coated vesicles.
KR100188302B1 (ko) 활성화피브린용해성과항-혈전성단백질
US5268358A (en) PDGF receptor blocking peptides
US20070100133A1 (en) Erythropoietic compounds
EP0745092B1 (fr) Peptides inhibiteurs de l'activite des recepteurs d'urokinase
JPH07503617A (ja) Ｔａｔ由来の輸送ポリペプチド
KR100545720B1 (ko) 당화된 면역글로불린 및 이를 포함하는 면역접합체
JP2012149069A (ja) 治療用ペプチド
JP2008505928A5 (fr)
WO1996004004A1 (fr) Compositions et procedes d'apport de medicaments par les plaquettes pour le traitement de maladies cardio-vasculaires
HU228068B1 (en) Protein for blocking platelet adhesion
KR100700753B1 (ko) 섬유소용해 활성을 갖는 변형된 피브롤라제 및 이의제조방법
WO1992011364A1 (fr) Antagonistes biosynthetiques de facteur de croissance plaquettaire
JP2000505300A (ja) 組換えリボヌクレアーゼタンパク質
JP2003513656A (ja) Ｆｃ分子中にミスフォールドされたジスルフィドの是正方法
NO314848B1 (no) Protein for inhibering av kollagenfremkalt blodplateaggregering, DNA som koder for proteinet, vektor som omfatter et slikt DNA, vertscelletransformert medvektoren, fremgangsmåter for fremstilling og rensing avproteinet, farmasöytiskpreparat
KR20030074796A (ko) 혈소판 당단백질 ｉｂ 알파 융합 폴리펩티드 및 이의 사용방법
AU646633B2 (en) Soluble analogs of thrombomodulin
WO2001085100A2 (fr) Proteines de fusion et conjugues contenant un vasodilatateur et un agent thrombolytique
JP4290564B2 (ja) Ｃ５ａアナフィラトキシンの突然変異タンパク質、このような突然変異タンパク質をコードする核酸分子ならびにＣ５ａアナフィラトキシンの突然変異タンパク質の医薬的使用
WO2007132481A2 (fr) Nouvelles molécules thrombolytiques et procédé associé
US5723312A (en) Collagen-induced platelet aggregation inhibitor
EP0979276B1 (fr) Sequences du type complement recepteur 1 (cr1)
JP2021525077A (ja) 断片化されたｇｒｓポリペプチド、その変異体及びこれらの用途
WO1992006999A1 (fr) Fragments therapeutiques du factor de von willebrand

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP